Validation and Digital Systems PIC/S and EU GMP Convergence

The Next Regulatory Alignment Wave

Global Good Manufacturing Practice (GMP) expectations are entering a new phase of GMP convergence. Regulatory across the Pharmaceutical Inspection Co‑operation Scheme (PIC/S) and the European Union (EU) have signalled a clear direction of travel: validation, data integrity, and computerised systems are no longer treated as parallel disciplines – they are being inspected as a single, connected capability.

PIC/S has opened public consultations on concept papers for Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation) with the Therapeutic Goods Administration (TGA) facilitating consultation in Australia. At the same time, the European Medicines Agency (EMA) has outlined near‑term work on documentation, data integrity and validation through planned updates to Chapter 4, Annex 11 and Annex 22 of the EU GMP Guide.

Taken together, these developments point to the next convergence wave in GMP inspections: systems‑based thinking, where digital records, validation lifecycle control and Pharmaceutical Quality System (PQS) governance are assessed as an integrated whole.

The GMP convergence pattern: validation, data integrity and computerised systems

Historically, inspections often examined validation, data integrity and computerised systems as discrete topics. That separation is rapidly eroding.

The EMA’s published work plan confirms coordinated updates to Chapter 4 (Documentation) and Annex 11 (Computerised Systems) specifically to strengthen data integrity, alongside a targeted revision of Annex 15 to reflect modern technologies and quality risk management principles (ICH Q9 (R1)). PIC/S concept papers similarly emphasise alignment with current industry practices, including the increased use of digital and computerised systems in manufacturing and validation activities.

The GMP convergence pattern is clear:

• Validation is no longer only about proving equipment and processes work.
• Data integrity is no longer only about ALCOA+ controls on records.
• Computerised systems are no longer only an IT or CSV concern.

Instead, regulators are increasingly assessing how well these elements function together across the system lifecycle, from design and supplier selection through to ongoing performance, review and improvement.

What manufacturers should expect from inspectors: systems‑based thinking

As GMP convergence accelerates, inspectors are shifting from document‑by‑document reviews to end‑to‑end system assessments.
Based on current regulatory signals, manufacturers should expect inspectors to explore questions such as:

• How does your validation lifecycle link to PQS governance and quality risk management?
• How do digital systems support, rather than undermine, data integrity and traceability?
• How do change management, periodic review and supplier oversight work together in practice?

The EMA’s plans explicitly highlight enhanced scrutiny of documentation, digital records and validation in the context of new technologies. This means inspectors are less interested in isolated validation reports and more focused on how organisations demonstrate ongoing control.

In practical terms, inspection discussions are becoming framed around:

• System intent and criticality
• Lifecycle ownership and accountability
• Evidence of effective oversight, not just compliance artefacts 

Practical inspection‑proofing moves: what “good” looks like

To respond to this shift, manufacturers are moving beyond reactive remediation towards inspection‑proofing and designing systems that are robust by default.

Common good‑practice moves include:

Strengthening traceability

• Clear linkage between user requirements, risk assessments, validation evidence and live system use.
• End‑to‑end traceability that inspectors can follow without interpretation gaps.

Formalising governance

• Defined ownership for digital systems and validated processes.
• PQS‑embedded decision forums for changes, deviations and periodic review.

Making periodic review meaningful

• Periodic reviews that assess continued fitness for intended use, not just checklist completion.
• Integration of performance data, deviations, audit findings and supplier issues into review outputs.

These approaches align with the direction of regulatory updates that reinforce lifecycle oversight rather than point‑in‑time validation. 

Supplier oversight: how digital evidence and validation packages will be judged

As manufacturers increasingly rely on external vendors for software, cloud platforms and automated systems, inspectors are focusing on how digital evidence from suppliers is evaluated and governed. The EMA’s work on computerised systems and documentation highlights heightened expectations for oversight and traceability across the supply chain.

In practice, inspectors are less persuaded by:

• Large, generic supplier validation packs
• Uncontextualised certificates or summary reports

And more interested in:

• How supplier documentation has been risk‑assessed and tailored to the intended use
• How responsibilities between sponsor and supplier are clearly defined
• How ongoing supplier performance is monitored post‑implementation

The question is no longer

“Did the supplier validate the system?”

but rather

“How did you assure this system remains compliant and fit for purpose within your PQS?”

A combined readiness checklist: PQS, CSV/CSA and Annex 15 lifecycle

One effective response to GMP convergence is a bringing together PQS, computer system validation (CSV) or computer software assurance (CSA), and Annex 15 lifecycle principles.

A high‑level readiness checklist typically considers:

• PQS alignment: roles, escalation pathways and quality oversight
• Risk‑based validation: system criticality, intended use and impact on product quality and data integrity
• Lifecycle control: change management, incident handling and periodic review
• Digital governance: access control, audit trails, backup and retention
• Supplier management: qualification, agreements and performance monitoring

This integrated approach mirrors the direction of regulatory updates rather than treating each discipline in isolation. 

How to triage gaps: risk‑based prioritisation

With multiple annexes and chapters evolving in parallel, many organisations face a familiar challenge: too many gaps and not enough time.

Risk‑based triage is essential. Manufacturers are:

• Prioritising systems and processes with the highest patient, product and data integrity impact
• Addressing cross‑cutting weaknesses (e.g. change management or governance gaps) before technical refinements
• Sequencing remediation to align with inspection exposure and business risk

This approach is consistent with the emphasis on quality risk management embedded in both PIC/S and EU GMP update programmes.

PharmOut can help manufacturers apply a practical, risk‑based triage to focus remediation on systems with the greatest patient, product and data integrity impact. By addressing cross-functional quality system and governance gaps first, PharmOut can support efficient sequencing of activities aligned to inspection exposure, business risk and evolving PIC/S and EU GMP expectations.

Preparing for the next inspection reality

The direction is clear: validation and digital systems are converging into a single inspection lens. Organisations that continue to manage CSV, data integrity and Annex 15 validation as separate workstreams risk falling behind regulatory expectations.

Those that succeed will be the ones that:

• Design integrated systems rather than layered controls
• Embed lifecycle thinking into their PQS
• Treat digital evidence as a core quality asset, not an IT by‑product

The next wave of inspections will reward coherence, clarity and control across the whole system, not just well‑written documents. 

PharmOut Services & Training

PharmOut supports manufacturers navigating evolving PIC/S and EU GMP expectations through risk‑based gap assessments, remediation planning and inspection‑ready validation strategies. Our consultants help prioritise high‑impact systems, address foundational quality system and governance weaknesses, and sequence remediation to align with inspection exposure and business risk. Our support spans computerised systems, validation packages, data integrity and PQS advisory services. We can help your organisation move from fragmented compliance to system‑level confidence.

We also deliver targeted training and practical workshops to help Quality, Engineering and IT teams build a shared understanding of evolving GMP expectations and inspection trends. Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.

Frequently Asked Questions (FAQ)